Directory · US
Biotechnology in United States
A register of firms and the professionals working at them in the Biotechnology sector based in United States. Browse the public index, then filter or export on Kipplo.
Companies
2.7K on file
Biotek Instruments
BioTek, now a part of Agilent Technologies, is a worldwide leader in the design, manufacture, and distribution of innovative life science instrumentation. Our comprehensive product line includes cell imaging systems, microplate readers, washers, dispensers, automated incubators, stackers and pipetting systems. These products enable life science research by providing high performance, cost-effective analysis and quantification of biomolecules, biomolecular interactions and cellular structure and function across diverse applications.
10001+ staff
Regeneron
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media.
10001+ staff
Eurofins Genomics Americas
Eurofins Genomics provides the fastest high-quality products and services in the genomics industry- Synthetic DNA (oligonucleotides) with hundreds of modification options and record-setting turnaround time - Specialized long RNA oligos with a large variety of modifications available - Gene Synthesis for individual genes or complete libraries using codon optimization software - Sanger Sequencing with overnight results anywhere in the US- Nanopore Sequencing for whole plasmids, amplicons, and bacterial genome samples. Same day results. Impeccable quality. As part of the Eurofins Scientific group, the clients of Eurofins Genomics enjoy the power of over staff in around 180 laboratories across 35 countries. Eurofins Scientific is the world leader in food and bio/ pharma products testing. Many of its labs are found here in the US and throughout the Americas. It is also number one in the world in the field of environmental laboratory services and one of the global market leaders in agroscience, genomics, pharma discovery services, and central laboratory services.
10001+ staff
Axygen
Founded and incorporated in 1993, Axygen Scientific is the leading global supplier of laboratory plastics for the research industry, including the pharmaceutical, biotech, and academia markets. Axygen, Inc. is now a part of Corning Incorporated.
10001+ staff
Abclonal Technology
Based in Massachusetts, ABclonal is a dynamic and growing provider of biology research reagents and services. With scientists from world-class universities, we thrive to improve the quality of life science research by providing high-quality antibodies, proteins, ELISA kits, NGS Prep Kits and molecular enzymes. ABclonal has a comprehensive prokaryotic and eukaryotic protein expression system, advanced mouse monoclonal antibody production system and a fourth-generation rabbit monoclonal antibody technology. Our advanced technology allows the development of in vitro diagnostic products and customized IVD materials used in the early research and development of raw materials development services.#Biotechnology #LifeScience #Antibody #ResearchTools
501 to 1000 staff
Arcus Biosciences
Arcus Biosciences is a rapidly growing, clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines that may have the potential to help people with cancer live longer. Located in the San Francisco bay area, Arcus Biosciences offers a competitive compensation and benefits package, including aggressive participation in the growth of the company in the form of stock option grants. Arcus has an ambitious undertaking and expects to become a force in the discovery, development and commercialization of novel combination therapies to treat cancer in areas of high unmet need. Our employees enjoy operating in an exceptionally dynamic and team-driven environment in which the “rule book” has not yet been written.
501 to 1000 staff
Nektar Therapeutics
Since its inception, Nektar has led with scientific ingenuity, unwavering resilience and a bold commitment to improving patients’ lives. We have built expertise spanning foundational scientific research, cutting-edge therapeutic discovery, clinical development, strategic partnerships and commercialization – all in pursuit of opportunities to improve outcomes for people with immune-mediated disease. Through the years, we have developed a proven track record of translating groundbreaking research into innovative therapies in partnership with leading pharmaceutical companies. We remain focused on advancing scientific discoveries into safer, more effective treatments for people living with autoimmune diseases and inflammatory conditions.
51 to 200 staff
Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on our patented DNA delivery technologies and other therapeutic approaches. Headquartered in San Diego, CA, Vical is independently pioneering the development of paradigm-changing therapies, and is partnering with key industry leaders. Additional information on Vical is available at
11 to 50 staff
Adaptive Biotechnologies Corp
Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems. Adaptive’s proprietary immune profiling platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Working with drug developers, clinicians and academic researchers, we are applying these insights to develop products that will transform the way diseases - such as cancer, autoimmune conditions, and infectious diseases - are diagnosed and treated. For more information, please visit adaptivebiotech.com.
501 to 1000 staff
Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. For additional information on our guidelines, please visit Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Allogene Therapeutics positions are accessible via the Allogene Careers page at
201 to 500 staff
Atum
ATUM is an industry-leading provider of life science tools and solutions. Founded as DNA2.0 in 2003, we were a pioneer in the application of machine learning to synthetic biology and currently hold multiple patents covering several technologies, including our first-to-market Leap-In Transposase® platform. Our integrated offerings include Gene Design & Synthesis, Protein Production, and Cell Line Development — all powered by our Leap-In Transposase® and machine learning platform. This means a streamlined path from sequence to Research Cell Bank (RCB) with just a click, ensuring efficiency, regulatory compliance, and innovative solutions tailored to our clients' needs. ATUM is privately held and is headquartered in Newark, CA.
51 to 200 staff
Beta Bionics
Beta Bionics is a commercial stage medical technology company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWDs) by utilizing advanced adaptive algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared autonomous insulin delivery device in the market and offers the potential to substantially improve overall outcomes across broad populations of PWDs. To learn more, visit For safety information, visit:
201 to 500 staff
Biobridge Global
BioBridge Global, a San Antonio-based 501(c)(3) nonprofit, integrates donor-to-patient services to enable the future of biotherapeutic solutions, including blood, tissue and advanced therapies. Through its subsidiaries – South Texas Blood & Tissue, QualTex Laboratories and BBG Advanced Therapies – BioBridge Global provides products and services in blood resource management, cellular therapy manufacturing, donated umbilical cord blood and human tissue, as well as testing of blood, plasma, tissue and cellular products for clients in the United States and international markets. It supports the development of advanced therapies by providing access to starting materials, testing services, biomanufacturing and clinical trials support. BioBridge Global is committed to saving and enhancing lives through the healing power of human cells and tissue. Learn more at BioBridgeGlobal.org. You can also find us on Twitter at @BioBridgeGlobal.
501 to 1000 staff
Biofire Defense
BioFire Defense is a proud member of the bioMérieux family — we play a critical role in helping to make the world a healthier place. We are on a mission to Align Readiness across government agencies protecting us from biothreats and emerging infectious diseases. We execute our mission focused on purposeful innovation, advancing global health security, and delivering uncompressing quality to our partners in the U.S. government, military, and public health agencies. BioFire Defense empowers government agencies, first responders, and healthcare professionals with actionable biothreat detection and diagnostic intelligence — protecting health and ensuring readiness against evolving threats.
51 to 200 staff
Biolife Solutions, Inc
Preserving the Promise™ The human body can heal itself. Cell and gene therapies are designed to augment the patient’s ability to fight disease but only if the living cells behind those therapies remain viable and functional throughout the production processes. At BioLife Solutions, our mission is to protect the integrity of cells and provide trusted tools, services, and expertise that can enable our customers to advance the development and delivery of cell and gene therapies. We believe the future of cell and gene therapies hinges on the integrity of every single cell and we are here to preserve that promise. For more information, please visit and follow BioLife on LinkedIn, Facebook and X. We are a publicly traded company listed on the NASDAQ under the ticker symbol BLFS.
201 to 500 staff
Boston Heart Diagnostics
Boston Heart Diagnostics is transforming the treatment of cardiovascular disease by providing healthcare providers and their patients with novel, personalized diagnostics and reports and integrated customized lifestyle programs that have the power to change the way clinicians and patients communicate about disease and improve heart health. Boston Heart looks beyond the “good” and “bad” cholesterol assessment that conventional labs provide to give a more complete and individualized picture of heart health. Founded by renowned cardiovascular researchers and led by seasoned lab and diagnostic executives, Boston Heart is one of the fastest growing health companies in the country. For more information on Boston Heart Diagnostics, please visit Current Career Opportunities Visit our website for a complete list of career opportunities:
201 to 500 staff
C4 Therapeutics, Inc
C4 Therapeutics (C4T)(Nasdaq: is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes.
51 to 200 staff
Celularity Inc
Celularity, headquartered in Florham Park, N.J, is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics. Celularity’s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the postpartum placenta. Through nature’s immunotherapy engine – the placenta – Celularity is leading the next evolution of cellular medicine with placenta-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases. To learn more visit celularity.com.
51 to 200 staff
Champions Oncology, Inc
Champions Oncology, Inc. provides an end-to-end range of research and development solutions and services that improve the productivity of oncology drug development. Using both in vitro to in vivo testing platforms companies can leverage the expertise at Champions Oncology to help guide decision making for clinical development scenarios. From screens using commercially-available and custom cell lines, to studies leveraging syngeneic or traditional patient-derived studies xenograft (PDX) models, and modeling treatment response in the clinic, Champions Oncology is your partner in meeting today’s needs and innovating for tomorrow’s challenges. At the core of our services is the Champions TumorGraft® (CTG) platform, a comprehensive, unique compendium of PDX models that preserve the biological characteristics of human tumors and are highly predictive of clinical outcomes. Services utilizing Champions TumorGrafts® PDX tumor models include evaluating tumor sensitivity/resistance to various single, combination, standard and novel chemotherapy agents, biomarker discovery and the identification of novel drug combinations. Champions TumorGraft® PDX models are procured through agreements our Clinical Collaboration Network, a series of renowned oncology institutions in the US and around the world, as well as through the company’s Personalized Oncology Solutions business. Personalized Oncology Solutions assist clinical oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients’ cancer tissues, as appropriate. Additionally, the company offers personalized PDX development, drug studies and genome sequencing, whereby physicians evaluate the effects of cancer drugs and understand the genetic makeup of each patient’s tumor, enabling them to better select treatment regimens.
201 to 500 staff
Dow Agrosciences
Dow AgroSciences was acquired by Corteva Agriscience. To see what’s new, visit Corteva Agriscience at
5001 to 10000 staff
Drugscan
Drugscan is a national toxicology and infectious disease testing laboratory that partners with organizations and providers to provide the critical testing they need for healthier lives and safer workplaces. Founded in 1985, Drugscan has more than 35 years of experience in toxicology testing via their CAP-and SAMSHA-certified laboratories. Drugscan is a leading pioneer in providing prescription drug and addiction monitoring, specialized drug testing, and workplace drug testing, screening and program management services to clients in 48 states. Drugscan also provides infectious disease testing services, including real-time PCR testing for COVID-19, through their ViraScan laboratory. Drugscan’s corporate office and state-of-the-art laboratories are in Horsham, PA.
51 to 200 staff
Germfree
Germfree provides controlled aseptic environments as well as primary and secondary containment to serve the rigorous demands of our clients. Our laboratory equipment, cleanrooms, cGMP facilities and biosafety labs deliver solutions across the complete life science spectrum.
51 to 200 staff
Ieh Laboratories And Consulting Group
IEH is an international lab & consulting services company, offering a comprehensive portfolio of lab testing services and consultation across multiple industries. IEH works with food production plants and manufacturers to ensure that the products released into our global supply are tested, safe, and in compliance with regulatory standards. Since 2001, IEH has expanded it's reach to service over 10 countries, with more than 100 locations covering the United States, Canada, Mexico, Germany, England, Austria, Poland, Netherlands, China, and Australia. Our lab services include but are not limited to food microbiology, analytical chemistry, allergen testing, GMO testing, authenticity testing, claim and forensic analysis, molecular epidemiology, and FDA detention. Our consulting team provides innovative and proven food safety solutions by designing and implementing testing programs to reduce risks associated with food production, and provides crisis management and regulatory support to our food partners.
1001 to 5000 staff
Indica Labs
Indica Labs is the global leader in AI-powered digital pathology software and services. Our flagship HALO® and HALO AI platform revolutionizes quantitative evaluation of whole slide images. HALO Link provides collaborative image management while HALO AP® and HALO AP Dx deliver enterprise digital pathology for primary diagnosis with regulatory clearances in multiple markets. Through a commitment to open pathology, performance, scalability, and ease-of-use, we help pharma companies, diagnostic labs, hospitals, research organizations, and Indica’s own Cloud and Pharma Services make discoveries and diagnoses that transform patient care and scientific discovery.
51 to 200 staff
Inventprise
At Inventprise, developing innovative and widely available vaccines is in our DNA. By producing targeted vaccines for populations worldwide, we're addressing global health inequalities and empowering people to live healthy lives—no matter where they live. Headquartered in Redmond, WA, our goal is to deliver widely-available, effective vaccines at large-scale to Low and Middle Income Countries, as well as populations in the U.S. and around the world. Inventprise is committed to creating a diverse and inclusive workplace, where our people are inspired to do their best work. We’re proud to have some of the world’s most qualified industry scientists, researchers, and manufacturing professionals on our team, and strive to create a vibrant, dynamic presence in the Washington State Life Sciences environment. Learn more about Inventprise and view open roles at to become a part of our growing team.
51 to 200 staff
Maxcyte, Inc
We invest in our partners early on, working side by side in optimizing their processes to derisk their path to the clinic faster. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health.
51 to 200 staff
Menarini Silicon Biosystems
Menarini Silicon Biosystems (MSB) is the only CLIA lab that offers circulating tumor cell (CTC) enumeration and phenotyping with CellSearch® as well as comprehensive genomic profiles of tumor cell-fee DNA and RNA (cfDNA/RNA) with MenariniSearch. The CellSearch® platform is the Gold Standard of CTC technology and offers a minimally invasive approach to follow your cancer patient’s therapeutic journey through standardized enumeration of circulating tumor cells and biomarker testing in solid tumors and multiple myeloma. MenariniSearch comprehensive genomic profiles detect a broader range of genetic alterations, to discover novel biomarkers and therapeutic targets that could enhance patient care. MenariniSearch tests use next-generation sequencing powered by artificial intelligence and are available for most cancer types. MSB’s tests are CLIA and CAP accredited LDTs that are reviewed by pathologists and can be performed on peripheral blood, cerebrospinal fluid, tissue, and bone marrow. Menarini Silicon Biosystems, based in Huntingdon Valley, PA, US, is a wholly-owned subsidiary of the Menarini Group, a multinational pharmaceutical, biotechnology, and diagnostics company headquartered in Florence, Italy, with 17,640 employees in 136 countries. Read our Netiquette here:
51 to 200 staff
New York Genome Center
The New York Genome Center (NYGC) is an independent, nonprofit academic research institution focused on furthering genomic research that leads to scientific advances and new insights and therapies for patients with neurodegenerative disease, neuropsychiatric disease, and cancer. Leveraging our strengths in whole genome sequencing, genomic analysis, and development of genomic tools, the NYGC serves as a nexus for collaboration in genomic research for the New York community and beyond.
51 to 200 staff
Nurix Therapeutics
Important Notice to Candidates: Nurix representatives with never conduct interviews by text and will never request personal financial information or ask candidates to purchase equipment. At Nurix Therapeutics, we aim to fundamentally change the way disease is treated using degrader-based medicines. Our journey began with a vision to harness the power of the cell’s natural protein degradation machinery, the ubiquitin-proteasome system, to create a new class of therapeutics that can overcome the limitations of current treatments.
201 to 500 staff
Protrials Research, Inc
ProTrials Research, Inc, is a full-service clinical research organization (CRO) and woman-owned business headquartered in Los Gatos, CA, with clinical operations personnel located throughout North America and across the world. ProTrials works with sponsors in the pharmaceutical, biotechnology and medical device industries to deliver high-quality clinical development services in a wide range of therapeutic areas. Founded in 1996, ProTrials has been successfully supporting clinical research for over 27 years.
51 to 200 staff
Rocket Pharmaceuticals
Rocket Pharma (NASDAQ: RCKT) is a fully-integrated, clinical-stage company seeking gene therapy cures. Rocket places enormous value on people and takes team member progress and well-being just as seriously as the progress and well-being of its pipeline. We are looking for hands-on team players that enjoy collaborating with colleagues who share a passion for our mission and making a difference for patients. Become an integral part of an agile, highly productive team and help grow an entrepreneurial, scientifically driven organization that is increasingly recognized as a leading biotechnology innovator. In addition to a competitive compensation package featuring a generous 401K match and stock options, positions include excellent health benefits. For more information, please visit Twitter: https://bit.ly/2O28aHx YouTube: https://bit.ly/3iNSXIu
201 to 500 staff
Taysha Gene Therapies
Taysha Gene Therapies is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside.
51 to 200 staff
Theravance Biopharma Us, Llc
Theravance Biopharma aims to transform the treatment of specialty respiratory and neurologic diseases by delivering Medicines that Make a Difference® in patients’ and caregivers’ lives. In pursuit of our purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Our pipeline of internally discovered programs is targeted to address significant unmet patient needs. As a spin-off of Theravance, Inc, Theravance Biopharma, Inc. was founded in 2014 and has offices in South San Francisco, and Dublin, Ireland. We are a place for collaborators and creative problem-solvers – people who thrive on applying insight and innovation to discovering novel medicines. We invite you to explore our job opportunities and learn more about what Theravance Biopharma has to offer You can also connect with us on Twitter at @TheravanceBio. Please visit for more information on how to engage with Theravance Biopharma on social media.
51 to 200 staff
Xencor
Proteins by Design Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs.
201 to 500 staff
Clear Labs
Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for clinical and applied markets. By creating a fully automated platform that brings together DNA sequencing, robotics and cloud-based analytics, Clear Labs democratizes genomics applications to deliver increased clarity. Clear Labs’ turnkey platform accelerates outcomes and improves accuracy - from food-borne pathogens to infectious diseases, including SARS CoV-2. With a novel approach, Clear Labs is helping the world better understand, track and mitigate tomorrow’s novel pathogens.
51 to 200 staff
Cti Biopharma
We have merged with Sobi AB creating a biopharma company positioned to provide innovative medicines that transform the lives of people with rare and debilitating diseases. Visit to continue to learn more about our work. For more information on the acquisition, see our press release at: https://bit.ly/42XKW9M
51 to 200 staff
Larimar Therapeutics Inc
Larimar Therapeutics, Inc.(Nasdaq:LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
11 to 50 staff
Locus Fermentation Solutions
Locus Fermentation Solutions (Locus FS) uses patented biomanufacturing technology to deliver biological alternatives to chemicals that accelerate the profitable meeting of decarbonization goals for clients. These solutions are tailored to address global ESG challenges—including climate change, food security, product sustainability, water contamination, oil and mineral demand, and more. Once field proven, the biobased ingredients are commercialized through industry-specific operating divisions. Locus Fermentation Solutions’ divisions include Locus Agriculture, which helps farmers grow more food and minimize greenhouse emissions; Locus Animal Nutrition, which reduces methane emissions while boosting productivity of livestock; Locus Bio-Energy, which works with oil & gas operators to sustainably increase production of low-carbon fossil fuels; Locus Mining, which accelerates the clean-energy transition by boosting recovery of critical metals; Locus Ingredients, which helps clients replace chemical and palm-based surfactants in industrial and product formulations; and Locus Consumer Brands, which develops clean-label CPG products. Locus FS has received more than 65 awards and recognitions, is actively advancing 11 of the 17 United Nations’ Sustainable Development goals, and is actively setting net-zero commitments across sectors. With 11 offices in five states, the company employs more than 160 people and brings together leading scientists and researchers from all over the world. For more information, visit LocusFS.com.
51 to 200 staff
Miraca Life Sciences
Inform Diagnostics, previously known as Miraca Life Sciences serves more than 5,500 patients each day, providing expert pathology services in the fields of dermatopathology, breast pathology, GI pathology, hematology/oncology pathology, and urologic pathology. Additionally, Miraca provides health IT consulting services, and has helped hundreds of practices with programs such as MIPS, quality reporting, Meaningful Use, security risk assessments, and HIPAA compliance. The company, previously known as Caris Diagnostics, was renamed Miraca Life Sciences in February 2012. In November 2017, Miraca Life Sciences was acquired by Avista Capital Partners. As a leader in anatomic pathology, Inform Diagnostics combines the rigor of an academic medical institution with the innovative spirit of a technology company. By working for Inform Diagnostics, you will have the opportunity to contribute alongside top multidisciplinary talented professionals, who are dedicated to meeting the needs of our clinician clients and their patients. You will work in a state-of-the-art environment with cutting-edge tools, breakthrough technologies and with world-renowned thought leaders. The company utilizes a forward-thinking business model seeking to make a profound difference in the quality of care for patients.
1001 to 5000 staff
Shimadzu Scientific Instruments
Headquartered in Columbia, Maryland, Shimadzu Scientific Instruments (SSI) is the American subsidiary of Shimadzu Corporation (Kyoto, Japan), a world leader in the development of scientific instruments. SSI was established in 1975 as a distribution center providing analytical solutions to a wide range of laboratories and lab services providers in the Americas. Today, SSI’s focus has expanded greatly beyond distribution. SSI maintains a network of ten regional offices strategically located across the United States, with experienced technical specialists, service and sales engineers situated throughout the country; a state-of-the-art Customer Training and Education Center; and Shimadzu U.S.A. Manufacturing, which supplies HPLC, GC-MS/MS, LC-MS/MS, and other high-tech products to the U.S. market. In addition, SSI operates a Solution Center, designed to allow more collaborative research and enable more applications development, and an Innovation Center that houses a team of engineers and scientists whose goal is to develop close collaborations with universities, government agencies, and industry centers. Shimadzu’s instruments are used by scientists throughout the Americas, and we count as customers some of the world’s leading institutions as well as a long list of local, state, and federal government laboratories. In addition, SSI is a leader in the academic community with a robust grant program and a SPARQ (Shimadzu Partnership for Academics, Research, and Quality of Life) program designed to build long-term relationships between the company and colleges/universities Shimadzu’s growth throughout its history is a testament to experience, technological expertise and customer service/support. Moving forward, Shimadzu will continue to develop and manufacture instruments that deliver results faster and more efficiently than ever before to meet the needs of researchers, scientists, and manufacturers around the globe.
501 to 1000 staff
22nd Century Group, Inc
22nd Century Group is a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology. GVB Biopharma is now a 22nd Century company.
51 to 200 staff
Agendia
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free. Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit For view our social media policies, please visit https://agendia.com/legal-compliance/
51 to 200 staff
Akadeum Life Sciences, Inc
Akadeum’s microbubble technology is the first GMP cell separation modality to solve all the challenges in the early steps of the cell therapy manufacturing process: time, cost, scalability, and performance. Microbubbles are flexible to integrate into any workflow and provide an increase in potency and persistence while enabling up to a 40% reduction in overall cell therapy manufacturing costs. Compatible with both centralized and decentralized manufacturing models, utilizing microbubbles for cell separation is the path to greater access and more cost-effective therapeutics. Healthier Cells. Better Therapies.
11 to 50 staff
Akouos
Healthy hearing available to all
51 to 200 staff
Alturas Analytics, Inc
At Alturas Analytics, we deliver results on time with the highest level of integrity. Our business is built on developing long term collaborations with our clients by providing advanced MS/MS solutions through a focused emphasis on teamwork, communication and exceptional science. Alturas has a proven record with complex analysis supporting drug candidates for the pharmaceutical and biotechnology industries, from discovery through phase IV clinical trials. The company operates in a GLP environment using validated operational processes in strict adherence to internal SOPs and applicable global regulations. Bioanalytical services routinely performed include the following: • GC-MS/MS and LC-MS/MS bioanalysis – allows for the broadest range of chemical properties across a wide mass range • GLP and non-GLP bioanalysis of large and small molecules in any matrix • Quantitative Antibody Drug Conjugates (ADC) analysis • Biomarker quantitation • Protein binding estimations • Dried Blood (DBS) and Matrix Spot (DMS) analysis (limited sample volume ex. pediatrics, CSF, tears) Ensuring that a project is completed on time to a company's specifications demands clear lines of communication before, during, and after a study's completion. Clients have direct access to a team of professionals who understand the critical nature of the business. An Alturas Study Director is assigned to each client based on their working knowledge with compounds of similar chemical properties. Comments & Feedback:"Thanks. We owe a lot to Alturas for the great nonclinical and clinical bioanalytical support for the program. Happy 2013!" January 2013: Comment from a Sponsor after receiving FDA Approval. “You solved all of our bioanalytical problems.” Comment from a Sponsor after the Alturas Team was able to address technical difficulties."Five Stars. Would definitely use Alturas again for upcoming projects." Comment from a Sponsor in 2016.
51 to 200 staff
Avance Biosciences, Inc
Avance Biosciences is a leading Contract Research Organization (CRO) and Contract Testing Organization (CTO) providing CGMP and GLP-compliant analytical and bioanalytical services to support drug development.
51 to 200 staff
Avidity Biosciences, Inc
DELIVERING ON OUR VISION Our vision is to profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics. We’re utilizing our proprietary AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) with the precision of oligonucleotide-based therapies in order to redefine RNA therapeutics and more effectively target underlying genetic drivers of diseases. We are delivering on this vision by investing in our platform, our pipeline and our people. Through this platform, we are pleased to share our ideas and company progress as we advance our science and overall mission to deliver breakthrough therapies to patients.
51 to 200 staff
Bioprocure, Llc
BioProcure aims to keep researchers in the lab - doing science! We partner with startup biotechs by providing services designed to streamline the entire procure-to-pay process, implement internal controls, and obtain savings. BioProcure offers a team of purchasing and accounting experts dedicated to your success. eProcurement allows scientists to optimize their lab time and provides a virtual bridge to finance and VCs, even when located remotely. Our extensive client list includes many cutting-edge startup biotech firms in the greater Boston area, as well as other biotech hubs.
51 to 200 staff
